Literature DB >> 30307686

Environmental temperature and case fatality of patients with Ebola virus disease in Sierra Leone and Liberia, 2014-2015: a retrospective cohort study.

Jillian L Peters1, Daniel K Cho2, Adam R Aluisio3, Stephen B Kennedy4, Moses B F Massaquoi5, Foday Sahr6, Shiromi M Perera7, Adam C Levine3,7.   

Abstract

OBJECTIVE: Fluid loss during Ebola virus disease (EVD) infections from gastrointestinal dysfunction leads to volume depletion. It is possible that high environmental temperatures may exacerbate volume depletion or interfere with the provision of medical care by providers in full personal protective equipment. We investigated the effect of environmental temperature on case fatality.
METHODS: The International Medical Corps (IMC) operated five Ebola Treatment Units (ETUs) in Liberia and Sierra Leone during the 2014-2016 epidemic. Demographic and outcomes variables for 465 patients with EVD were sourced from a de-identified, quality-checked clinical database collected by IMC. Daily environmental temperature data for Liberia and Sierra Leone were collected from a publicly available database (Weather Underground). Mean daily environmental temperatures were averaged across each patient's ETU stay and environmental temperature thresholds were determined. Multiple logistic regression was utilised, with forward variable selection and threshold for entry of P < 0.1. Statistical significance was defined as P < 0.05. The following variables were analysed as potential confounders: age, sex, ETU, length of ETU operation and date of treatment.
RESULTS: Case fatality was 57.6% among patients diagnosed with EVD. Analysis of case fatality across environmental temperature quintiles indicated a threshold effect; the optimal threshold for average environmental temperature during a patient's ETU stay was determined empirically to be 27.4 °C (81.3 °F). Case fatality was significantly greater for patients with average environmental temperatures above the threshold (70.4%) vs. below (52.0%) (P < 0.001). In multiple regression, patients with average environmental temperature above the threshold during their ETU stay were significantly more likely to die than patients below the threshold (aOR = 2.5, 95% CI 1.6-3.8, P < 0.001). This trend was observed only among patients treated in white tent ETUs, and not in ETUs with aluminium roofs. DISCUSSION: These findings suggest that an average environmental temperature above 27.4 °C (81.3 °F) during patients' ETU stay is associated with greater risk of death among patients with EVD. Further studies should investigate this effect. These results have potential implications for reducing case fatality through improved ETU construction or other temperature control methods within ETUs during future outbreaks.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ebola virus disease; environmental temperature; fièvre hémorragique virale; maladie du virus Ebola; mortality; mortalité; température environnementale; viral haemorrhagic fever

Mesh:

Year:  2018        PMID: 30307686      PMCID: PMC6324989          DOI: 10.1111/tmi.13166

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  16 in total

1.  Impact of personal protective equipment on clinical output and perceived exertion.

Authors:  Shelly Lyn Maynard; R Kao; D G Craig
Journal:  J R Army Med Corps       Date:  2015-10-28       Impact factor: 1.285

2.  Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients With Suspected Ebola Virus Disease.

Authors:  Adam C Levine; Pranav Prathap Shetty; Ryan Burbach; Sambhavi Cheemalapati; Justin Glavis-Bloom; Tess Wiskel; J Kota T Kesselly
Journal:  Ann Emerg Med       Date:  2015-04-03       Impact factor: 5.721

3.  Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone.

Authors:  Li-Qun Fang; Yang Yang; Jia-Fu Jiang; Hong-Wu Yao; David Kargbo; Xin-Lou Li; Bao-Gui Jiang; Brima Kargbo; Yi-Gang Tong; Ya-Wei Wang; Kun Liu; Abdul Kamara; Foday Dafae; Alex Kanu; Rui-Ruo Jiang; Ye Sun; Ruo-Xi Sun; Wan-Jun Chen; Mai-Juan Ma; Natalie E Dean; Harold Thomas; Ira M Longini; M Elizabeth Halloran; Wu-Chun Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

4.  Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study.

Authors:  Matthew Waxman; Adam R Aluisio; Soham Rege; Adam C Levine
Journal:  Lancet Infect Dis       Date:  2017-03-01       Impact factor: 25.071

Review 5.  Potential and emerging treatment options for Ebola virus disease.

Authors:  Bryan M Bishop
Journal:  Ann Pharmacother       Date:  2014-11-20       Impact factor: 3.154

6.  Prognostic Analysis of Patients with Ebola Virus Disease.

Authors:  Xin Zhang; Yihui Rong; Lijian Sun; Liming Liu; Haibin Su; Jian Zhang; Guangju Teng; Ning Du; Haoyang Chen; Yuan Fang; Wei Zhan; Alex B J Kanu; Sheku M Koroma; Bo Jin; Zhe Xu; Haihan Song
Journal:  PLoS Negl Trop Dis       Date:  2015-09-23

7.  The nexus between forest fragmentation in Africa and Ebola virus disease outbreaks.

Authors:  Maria Cristina Rulli; Monia Santini; David T S Hayman; Paolo D'Odorico
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

8.  Validation of a portable, deployable system for continuous vital sign monitoring using a multiparametric wearable sensor and personalised analytics in an Ebola treatment centre.

Authors:  Steven R Steinhubl; Dawit Feye; Adam C Levine; Chad Conkright; Stephan W Wegerich; Gary Conkright
Journal:  BMJ Glob Health       Date:  2016-07-05

9.  Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days.

Authors:  Boubacar Diallo; Daouda Sissoko; Nicholas J Loman; Hadja Aïssatou Bah; Hawa Bah; Mary Claire Worrell; Lya Saidou Conde; Ramata Sacko; Samuel Mesfin; Angelo Loua; Jacques Katomba Kalonda; Ngozi A Erondu; Benjamin A Dahl; Susann Handrick; Ian Goodfellow; Luke W Meredith; Matthew Cotten; Umaru Jah; Raoul Emeric Guetiya Wadoum; Pierre Rollin; N'Faly Magassouba; Denis Malvy; Xavier Anglaret; Miles W Carroll; Raymond Bruce Aylward; Mamoudou Harouna Djingarey; Abdoulaye Diarra; Pierre Formenty; Sakoba Keïta; Stephan Günther; Andrew Rambaut; Sophie Duraffour
Journal:  Clin Infect Dis       Date:  2016-09-01       Impact factor: 9.079

10.  Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients.

Authors:  Jin Li; Hui-Juan Duan; Hao-Yang Chen; Ying-Jie Ji; Xin Zhang; Yi-Hui Rong; Zhe Xu; Li-Jian Sun; Ji-Yuan Zhang; Li-Ming Liu; Bo Jin; Jian Zhang; Ning Du; Hai-Bin Su; Guang-Ju Teng; Yue Yuan; En-Qiang Qin; Hong-Jun Jia; Shu Wang; Tong-Sheng Guo; Ye Wang; Jin-Song Mu; Tao Yan; Zhi-Wei Li; Zheng Dong; Wei-Min Nie; Tian-Jun Jiang; Chen Li; Xu-Dong Gao; Dong Ji; Ying-Jie Zhuang; Lei Li; Li-Fu Wang; Wen-Gang Li; Xue-Zhang Duan; Yin-Ying Lu; Zhi-Qiang Sun; Alex B J Kanu; Sheku M Koroma; Min Zhao; Jun-Sheng Ji; Fu-Sheng Wang
Journal:  Int J Infect Dis       Date:  2015-10-30       Impact factor: 3.623

View more
  3 in total

1.  Association between multivitamin supplementation and mortality among patients with Ebola virus disease: An international multisite cohort study.

Authors:  Derrick Yam; Adam R Aluisio; Shiromi M Perera; Jillian L Peters; Daniel K Cho; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Michael A Smit; Lindsey Locks; Tao Liu; Adam C Levine
Journal:  Afr J Emerg Med       Date:  2020-01-03

2.  Persistence of Bacteriophage Phi 6 on Porous and Nonporous Surfaces and the Potential for Its Use as an Ebola Virus or Coronavirus Surrogate.

Authors:  Carrie Whitworth; Yi Mu; Hollis Houston; Marla Martinez-Smith; Judith Noble-Wang; Angela Coulliette-Salmond; Laura Rose
Journal:  Appl Environ Microbiol       Date:  2020-08-18       Impact factor: 4.792

Review 3.  Enterotoxigenic Escherichia coli Heat-Stable Toxin and Ebola Virus Delta Peptide: Similarities and Differences.

Authors:  Lilia I Melnik; Robert F Garry
Journal:  Pathogens       Date:  2022-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.